GLYX-13 is a synthetic peptide drug used in the treatment of depression and other mental illnesses. This compound is known for its ability to enhance synaptic plasticity and improve cognitive function.
Chemical Name:
GLYX-13 is also known as Rapastinel and NRX-1074.
Molecular Formula:
The molecular formula for GLYX-13 is C152H262N54O43.
Formula Weight:
The formula weight for GLYX-13 is 3425.12 g/mol.
CAS No:
The CAS number for GLYX-13 is 117928-94-6.
Top Ten Keywords from Google and Synonyms:
Health Benefits of this Product:
GLYX-13 is primarily used in the treatment of depression and other mental illnesses. It has been shown to have rapid and sustained antidepressant effects in both preclinical and clinical studies. It is also known to improve cognitive function and may have potential uses in the treatment of Alzheimer's disease and other neurodegenerative disorders.
Potential Effects:
GLYX-13 works by modulating the functioning of the N-methyl-D-aspartate (NMDA) receptor, which is involved in learning and memory processes. By enhancing synaptic plasticity, GLYX-13 is able to improve cognitive function and decrease symptoms of depression.
Product Mechanism:
GLYX-13 works as an NMDA receptor modulator by selectively enhancing the activity of the receptor's glycine-binding site. By enhancing the functioning of the NMDA receptor, GLYX-13 is able to promote synaptic strengthening and improve cognitive function.
Safety:
GLYX-13 is considered safe to use in clinical settings. However, it should only be administered by trained medical professionals and under strict supervision due to the potential risk of adverse effects.
Side Effects:
While GLYX-13 is generally well-tolerated, some adverse effects have been observed in clinical studies. These include nausea, headache, and dizziness. More serious side effects such as seizures have also been reported, although these are relatively rare.
Dosing Information:
The dosing information for GLYX-13 varies depending on the specific condition being treated and the patient's individual response to the drug. In clinical studies, GLYX-13 has been administered in doses ranging from 10 to 100 mg per injection.
Conclusion:
In conclusion, GLYX-13 (CAS: 117928-94-6) is a synthetic peptide drug used in the treatment of depression and other mental illnesses. This compound has the potential to enhance synaptic plasticity and improve cognitive function by modulating the functioning of the NMDA receptor. While GLYX-13 is generally considered safe to use, it should only be administered under strict medical supervision. If you have any questions or need more information about GLYX-13, it is recommended that you talk to a qualified healthcare professional.
